|
| | Volitinib Basic information |
| Product Name: | Volitinib | | Synonyms: | AZD6094,Volitinib, HMPL-504, Savolitinib;1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine;(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine;Volitinib;Savolitinib;HMPL-504(AZD6094, Volitinib);EOS-60799;AZD-6094) | | CAS: | 1313725-88-0 | | MF: | C17H15N9 | | MW: | 345.36 | | EINECS: | | | Product Categories: | API | | Mol File: | 1313725-88-0.mol |  |
| | Volitinib Chemical Properties |
| Melting point | 205-207°C | | density | 1.55±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 5.67±0.50(Predicted) | | form | Solid | | color | Pale Beige | | CAS DataBase Reference | 1313725-88-0 |
| | Volitinib Usage And Synthesis |
| Description | Savolitinib selectively inhibits the MET receptor, blocking the PI3K/AKT/MAPK-signaling
pathway as well as downregulating MYC. | | Uses | Savolitinib is a potent and highly selective c-Met inhibitor. Savoltinib demonstrated anti-tumor efficacy in a panel of cMet-dysregulated gastric cancer PDX models. Savolitinib also demonstrated good antitmuor activities. | | Clinical Use | It is currently being evaluated
in phase I clinical trials in combination with EGFR TKIs in NSCLC patients. |
| | Volitinib Preparation Products And Raw materials |
|
